Biopharma exits and returns nearly equaled 2018’s record year
Of the 50 venture-backed public offerings in 2019, 20 reached $1B+ market cap at year-end.
Dx/Tools realized most of its value in the public market
Two companies went public at a $2B+ valuation and positive post-IPO gains for the IPO class of 2019.
HealthTech IPOs emerged from a two-year drought
Four of the eight IPOs ended the year at $1B+ valuations.